Stereotactic ablative radiotherapy (SABR) for small lung tumors: retrospective analysis 2009-2010

• Conditions: C34; C78.0; Malignant neoplasm of bronchus and lung; Secondary malignant neoplasm of lung

• Registration Number: DRKS00003864
• Lead Sponsor: niversitätsklinikum Freiburg, Klinik für Strahlenheilkunde

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2011-12-31
• Study Start: 2016-02-18
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 39

Inclusion Criteria

presence of one or two FDG-PET positive pulmonary nodules - Karnofsky index >/= 60%
- Life expectancy > 6 months
- Age > 18 years (no other age limits)
- Informed consent signed in accordance with institutional protocol

Exclusion Criteria

- NSCLC: FDG-PET N+ if not ruled out by mediastinoscopy or other tissue sampling
- in metastases: disseminated progressive disease without local control to be reasonably expected by current treatment
- Histologically proven SCLC
- More than two lesions to treat
- Diameter of tumor > 5cm
- Systemic therapy +/- one week of treatment
- psychological/mental status does not allow informed consent and participation in QoL assessments
- Pregnancy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ocal progression-free survival rates after stereotactic ablative radiotherapy (SABR) for small lung tumors at one year and two years <br>(CT scans every 3 months or PET/CT respectively)

Secondary Outcome Measures

Name	Time	Method
overall survival, rate of toxicities